N
GRCE

Natixis’s Grace Therapeutics GRCE Stock Holding History

Natixis’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-263
Closed -$7K – 1286
2021
Q2 		$7K Buy
+263
New +$6.41K ﹤0.01% 848

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Natixis's GRCE Position: Q3 2021 in Review

Natixis sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 263 shares — an estimated $7K sold.

Natixis first reported a position in GRCE in Q2 2021 and held it in 1 quarter. The position peaked at $7K in Q2 2021. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

  • Natixis reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Natixis sold 263 Grace Therapeutics shares in Q3 2021, an estimated $7K.
  • Natixis first reported a position in Grace Therapeutics in Q2 2021 and held it in 1 quarter.
  • Natixis's Grace Therapeutics position peaked at $7K in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on Natixis's 13F filing for Q3 2021, filed 12 Nov 2021.